Cholesterol-Lowering Agents

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Loss-of-function variants in PCSK9 are linked to reduced atherosclerotic cardiovascular disease (ASCVD) risk.
• Genetic findings have been validated in clinical trials, informing risk stratification and understanding LDL-C lowering.

Purpose of the Study:

• To evaluate the efficacy and safety of markedly lowering LDL-C using PCSK9 inhibitors.
• To assess the impact of PCSK9 inhibition on cardiovascular events in high-risk populations.

Main Methods:

• Analysis of large, prospective clinical trials involving PCSK9 inhibitors.
• Evaluation of patient subgroups, including those with recent myocardial infarction, multiple myocardial infarctions, multivessel coronary artery disease, and lower extremity arterial disease.

Main Results:

• PCSK9 inhibitors demonstrate potent LDL-C lowering efficacy.
• Reductions in ASCVD events are more pronounced in specific high-risk patient groups.
• Aggressive LDL-C lowering with PCSK9 monoclonal antibodies shows a superior safety profile compared to other LDL-lowering agents.

Conclusions:

• PCSK9 inhibitors are effective in reducing cardiovascular events in high-risk patients, even with low baseline LDL-C levels.
• The findings support aggressive LDL-C lowering strategies and suggest no lower limit for LDL-C.
• PCSK9 inhibition offers a safe and effective therapeutic option for managing ASCVD.